Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $55.4 million.

  • Intellia Therapeutics' Accumulated Expenses fell 20.24% to $40.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year decrease of 20.24%. This contributed to the annual value of $55.4 million for FY2024, which is 17.40% down from last year.
  • As of FY2024, Intellia Therapeutics' Accumulated Expenses stood at $55.4 million, which was down 17.40% from $67.0 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Accumulated Expenses ranged from a high of $67.0 million in FY2023 and a low of $25.6 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $61.1 million, with a median of $60.9 million in 2022.
  • In the last 5 years, Intellia Therapeutics' Accumulated Expenses surged by 92.53% in 2020 and then fell by 17.40% in 2024.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Accumulated Expenses stood at $25.6 million in 2020, then surged by 69.48% to $43.3 million in 2021, then surged by 40.56% to $60.9 million in 2022, then increased by 10.09% to $67.0 million in 2023, then decreased by 17.40% to $55.4 million in 2024.